FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a pharmaceutical composition for treating TNF alpha-associated diseases in a mammal, which comprises an antibody, which contains specific sequences of light chain and heavy chain, which are optimized in terms of stability, solubility, binding with TNF in in vitro and in vivo and low immunogenicity.
EFFECT: invention widens the range of preparations for treating TNF alpha-associated diseases in a mammal.
16 cl, 12 dwg, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2018 |
|
RU2678120C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2653753C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα | 2009 |
|
RU2567100C2 |
| HUMANIZING RABBIT ANTIBODIES USING A UNIVERSAL ANTIBODY FRAMEWORK | 2018 |
|
RU2696202C1 |
| HUMANIZATION OF RABBIT ANTIBODIES USING THE UNIVERSAL ANTIBODY FRAME | 2014 |
|
RU2652907C2 |
| HUMANISATION OF RABBIT ANTIBODIES USING UNIVERSAL ANTIBODY SCAFFOLD | 2009 |
|
RU2567006C2 |
| VEGF INHIBITING STABLE AND SOLUBLE ANTIBODIES | 2009 |
|
RU2531523C9 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2009 |
|
RU2588467C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| STABLE AND SOLUBLE VEGF INHIBITING ANTIBODIES | 2018 |
|
RU2696972C1 |
